Age-Related Macular Degeneration
Actively Recruiting
ATMOSPHERE
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
HONU
The purpose of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced AMD stages.
DRCR AO
Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD (Protocol AO)
Age-Related Macular Degeneration
Enrollment Closed
PULSAR
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration (PULSAR)
GALE
To assess the long-term efficacy and safety of multiple intravitreal injections of APL-2 in subjects with geographic atrophy secondary to age-related macular degeneration.
Choroidal Melanoma
Actively Recruiting
AURA 301
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Intermediate Lesions or Small Choroidal Melanoma.
DRCR AL
A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy (Protocol AL)
Choroidal Melanoma
Enrollment Closed
AURA 201
A Phase 2 Trial of AU-011 Via Suprachoroidal Administration with a Dose Escalation Phase (Open-label, Ascending Single and Repeat Dose) and a Randomized, Masked Dose Expansion Phase Designed to Evaluate the Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Cornea
Actively Recruiting
Scleral Lenses for Dry Eye
Scleral Contact Lens Reduction of Cytokines in Dry Eye Patients
RECORDATI MT8
Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops (MT8) for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients
CapriCORN
Comprehensive Analysis of Pathogens, Resistomes, and Inflammatory-markers in the Cornea
KOWA 301
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD).
KOWA 303
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD).
NEXPEDE-1
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1).
Cornea
Enrollment Closed
Zoster Eye Disease Study (ZEDS)
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Suppressive Valacyclovir for One Year in Immunocompetent Study Participants with an Episode of Dendriform Epithelial Keratitis, Stromal Keratitis, Endothelial Keratitis, and/or Iritis Due to Herpes Zoster Ophthalmicus (HZO) in the Year Prior to Enrollment (ZEDS)
Genetics
Actively Recruiting
GENETIC EYE DISORDERS
To identify the gene or genes responsible for developmental causes of blindness in the world, and to establish a Pediatric Ophthalmic Genetics and Research Program at the University of Wisconsin – Madison.
MYOPIA
To identify genes that are involved in eye growth specifically in individuals and families with nearsightedness (myopia).
Glaucoma
Actively Recruiting
COAST
Clarifying the Optimal Application of SLT Therapy Trial (COAST)
Inherited Retinal Diseases
Actively Recruiting
UNI-RARE
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated with Rare Disease-Causing Genetic Variants
NAC Attack
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double-Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa.
POLARIS
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene (POLARIS)
Inherited Retinal Diseases
Enrollment Closed
SOLSTICE
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Treated Previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study (SOLSTICE)
Pro-EYS
Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS).
Oculoplastics
Actively Recruiting
TED
A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)
IMVT TED
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
IMVT TED Extension
An Open-Label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)
Uveitis
Actively Recruiting
MICROBIOME
To compare the gut microbiota composition in pediatric Juvenile Idiopathic Arthritis (JIA) uveitis patients to JIA patients without uveitis and to healthy controls.
IZOKIBEP (IL-17A)
To assess the safety, tolerability, and immunogenicity of izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.
SANDCAT
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Uveitic Macular Edema (Sandcat)